450 Participants Needed

Memsorb for Anesthesia Management

(memsorb Trial)

KS
VL
Overseen ByVera Lloyd
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: DMF Medical Incorporated
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the drug memsorb for anesthesia management?

The research suggests that adding dexmedetomidine to pain management can reduce the need for other pain medications like meperidine, which may imply that memsorb, if it includes similar components, could be effective in managing anesthesia by potentially reducing the amount of other drugs needed.12345

How is the drug memsorb different from other anesthesia management drugs?

Memsorb, also known as mesna, is unique because it acts as a protective agent against oxidative stress and tissue damage, which is not a common feature of typical anesthesia management drugs. It is known for its ability to neutralize harmful substances and protect tissues, which may offer additional benefits during anesthesia.678910

Research Team

OH

Orlando Hung, MD

Principal Investigator

Nova Scotia Health Authority

Eligibility Criteria

This trial is for English-speaking patients with a low to medium risk status (Class I, II, III) according to the American Society of Anesthesiologists. It's not suitable for pregnant individuals, high-risk patients (Class IV), those needing emergency surgery, or people with elevated brain pressure or severe respiratory diseases like COPD and asthma.

Inclusion Criteria

American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient)
I speak English.

Exclusion Criteria

Self-reported as pregnant
American Society of Anesthesiologists Physical Status Class IV (high risk patient)
I am scheduled for an emergency surgery.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive standard care using either the memsorb CO2 filter or a standard CO2 absorber during surgery

Up to 12 hours
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including measurements of various physiological parameters

1-2 weeks

Treatment Details

Interventions

  • memsorb
Trial OverviewThe study is testing 'memsorb', an innovative method aimed at removing CO2 from anesthetic circuits without using chemical granulate. This could potentially reduce harmful compounds, costs, environmental impact and the need for daily disposal of special waste.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: memsorbExperimental Treatment1 Intervention
Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
Group II: ControlActive Control1 Intervention
Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.

Find a Clinic Near You

Who Is Running the Clinical Trial?

DMF Medical Incorporated

Lead Sponsor

Trials
3
Recruited
520+

Findings from Research

In a study of 90 cancer surgical patients, intrathecal dexmedetomidine showed less immunosuppressive effects compared to morphine alone and the combination of morphine and dexmedetomidine, particularly in reducing cellular immunity markers post-surgery.
The use of dexmedetomidine also resulted in more favorable inflammatory mediator profiles, with lower levels of IL-10 and IL-1beta compared to morphine, suggesting it may be a better option for managing postoperative pain without compromising immune function.
Immunosuppressive Effect of Intrathecal Morphine, Dexmedetomidine, or Both in Combination with Bupivacaine on Patients Undergoing Major Abdominal Cancer Surgery.Kamal, SM., Mohamed, SA., Fares, KM., et al.[2022]
The use of Anesthesia Information Management Systems (AIMS) for perioperative outcomes research has significantly increased since 2001, highlighting its growing importance in understanding patient outcomes during surgery.
AIMS have proven effective in addressing complex clinical issues, such as risk stratification and rare complications like malignant hyperthermia, which traditional research methods struggle to analyze due to the unique challenges of anesthesia practice.
Anesthesia Information Management Systems: An Underutilized Tool for Outcomes Research.Deng, F., Hickey, JV.[2018]
In a study of 40 patients undergoing elective abdominal surgery, the combination of dexmedetomidine with meperidine in a patient-controlled analgesia (PCA) device significantly reduced postoperative pain scores compared to meperidine alone.
Patients receiving the meperidine-dexmedetomidine combination consumed less meperidine both in the postanesthesia care unit and up to 24 hours after surgery, indicating that dexmedetomidine enhances the efficacy of meperidine for pain management.
Comparison of meperidine alone with meperidine plus dexmedetomidine for postoperative patient-controlled analgesia.Altindis, NT., Karaaslan, D., Peker, TT., et al.[2010]

References

Immunosuppressive Effect of Intrathecal Morphine, Dexmedetomidine, or Both in Combination with Bupivacaine on Patients Undergoing Major Abdominal Cancer Surgery. [2022]
Anesthesia Information Management Systems: An Underutilized Tool for Outcomes Research. [2018]
Comparison of meperidine alone with meperidine plus dexmedetomidine for postoperative patient-controlled analgesia. [2010]
[Anesthesia management may alter long-term outcome-review of recent reports]. [2018]
Outcomes in perioperative medicine and anesthesiology. Into the next millennium. [2019]
Prophylaxis with mesna prevents oxidative stress induced by ischemia reperfusion in the intestine via inhibition of nuclear factor-kappaB activation. [2018]
Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. [2022]
The Effects of MESNA on the Facial Nerve, an Experimental Animal Study. [2020]
The effects of sodium-2-mercaptoethanesulfonate application on the neural and neurovascular tissues: An experimental animal study. [2020]
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). [2019]